T

TransMedics

Ex-vivo organ perfusion platform

HR Operations Specialist

Contract
No salary listed
Junior
Associate's
Andover, MA, USA
In PersonOn-site five days per week in Andover, Massachusetts.
People & HRHR Operations & Coordination

About the job

Requirements
  • Two years of experience in data entry using Workday Human Capital Management.
  • An associate degree is required.
Responsibilities
  • Enter, update, and maintain employee data in Workday, including job changes, terminations, compensation updates, job profiles, and compensation records.
  • Conduct regular data audits to ensure accuracy, completeness, and data integrity.
  • Identify, correct, and resolve data errors or discrepancies in a timely manner.
  • Follow established data-entry standards, workflows, and approval processes within Workday.
  • Provide HR operational support during high-volume periods such as open enrollment, performance cycles, and merit increases.
  • Assist with basic reporting and data extracts as requested.
  • Document and maintain data-entry procedures, guidelines, and updates.
  • Respond to routine HR or system-related inquiries related to employee data.
  • Support onboarding activities, including new-hire orientation and reviewing new-hire data for accuracy.
  • Ensure compliance with data-privacy, security, and regulatory requirements.
  • Perform additional TransMedics duties and responsibilities as assigned.
  • Support the Senior HR Operations Specialist with initiating one-time payments.
  • Support HR business partners with initiating job changes and terminations.
  • Support the Senior Director, Total Rewards with creating and maintaining job-profile data.
  • Support Talent Acquisition with job-requisition updates.
Desired Qualifications
  • Experience with Workday EIBs and data uploads.
  • Strong attention to detail and accuracy.
  • Ability to work with confidential and sensitive information.
  • Basic proficiency with Microsoft Excel and data-entry tools.
  • Strong organizational and time-management skills.
  • Ability to follow standardized processes and meet deadlines independently.
  • Familiarity with HR concepts such as onboarding, job changes, or payroll data.
  • Experience working in an HR, payroll, or administrative environment.
  • Confidence working with high volumes of confidential data.

About the company

TransMedics makes the Organ Care System (OCS), a portable platform that keeps donor organs alive outside the body by warm, oxygenated perfusion and continuous viability monitoring. The OCS circulates warmed, nutrient-rich blood through the organ, allowing surgeons to assess health in near-physiological conditions. Revenue comes from selling OCS consoles, disposable sets used per procedure, and the National OCS Program, which provides end-to-end organ retrieval and logistics services. It distinguishes itself by holding FDA approvals to preserve and assess hearts, lungs, and livers in the United States and by integrating hardware, consumables, and logistics to expand transplant opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 21% to $189.9 million, and guidance increased to $737-$757 million.
  • FDA approved ENHANCE Heart and DENOVO Lung IDEs in January-February 2026, advancing next-generation trials.
  • PAD Aviation closed July 6, 2026, opening pan-European transplant logistics contracts.

What critics are saying

  • Judge Sorokin partially denied dismissal July 21, 2026, forcing discovery in the fraud case.
  • CHOPS and kidney development burn cash while gross margin slipped to 60% in Q2 2026.
  • A bad ENHANCE or DENOVO safety signal in 2026-2027 would damage OCS credibility.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. warm-perfusion platform for hearts, lungs, and livers.
  • The National OCS Program bundles surgeons, logistics, aircraft, and disposables into a sticky ecosystem.
  • PAD Aviation extends TransMedics' logistics moat into Europe, copying the U.S. NOP playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Short Term Disability

Long Term Disability

Health Savings Account/Flexible Spending Account

Dependent Care Flexible Spending Account

401(k) Plan

Pet insurance

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Oct 1st, 2026
TransMedics director buys $109K in stock amid 30% yearly decline

David Weill, a director at TransMedics Group, purchased 1,336 shares of common stock for approximately $109,000 on 11 September 2026, according to an SEC Form 4 filing. The purchase increased his direct holdings by 9% to 16,392 shares, valued at roughly $1.4 million. The transaction occurred as the stock recorded a one-year return of -30%. TransMedics, a commercial-stage medical technology company with a market capitalisation of $2.7 billion, develops the Organ Care System, a portable device that preserves and monitors donor organs for transplantation. The company reported trailing twelve-month revenues of $668.5 million and net income of $151.7 million. Management has guided for 22%-25% sales growth in 2026 as it expands internationally and develops new platforms.

Yahoo Finance
Sep 15th, 2026
TransMedics and SoFi stocks fall 28% and 34% but show strong buying potential

TransMedics Group and SoFi Technologies have declined 28% and 34% respectively over the past year, presenting potential buying opportunities despite broader market strength driven by tech giants. TransMedics, which developed the Organ Care System for transplants, faces near-term headwinds. Second-quarter revenue grew 21% year over year to $189.9 million, marking a slowdown from recent quarters. Adjusted earnings per share fell 52% to $0.44. However, the company is investing in expansion initiatives, including potential kidney transplant approval and a logistics network for greater control over the organ transplant cycle. These investments are pressuring current profits but could drive future growth. The OCS technology maintains organ temperature and blood supply during transport, addressing limitations of traditional cold storage methods. With a large addressable market remaining, the stock may offer value at current levels.

PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.